U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions of people who got one last year.

RSV vaccine sales by GSK and Pfizer have dropped in the U.S. after regulators limited the eligible age group, affecting millions. Demand has decreased significantly during the autumn vaccination season,

The UK High Court has ruled that two GSK respiratory syncytial virus (RSV) vaccine patents are invalid in an action involving Pfizer, as both companies battle to become the first to launch an RSV vaccine on the UK market.

Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus (RSV) vaccine. The two pharmaceutical giants are among a number of companies in competition for a vaccine for RSV,

This is the first RSV vaccine approved in Singapore for use in older adults and pregnant individuals, providing critical protection to infants and seniors

A GSK spokesperson said 9 million Americans, or two-thirds of the market, have been vaccinated against RSV with Arexvy and that the company sees opportunities for strong growth in

Pfizer (NYSE:PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (NYSE:GSK) patents for its RSV vaccine. The ruling is part of ongoing litigation between the two drugmakers over their respective RSV vaccines.